ADCT Projected Dividend Yield

Ord/ADC Therapeutics SA ( NYSE : ADCT )

ADC Therapeutics is a biotechnology company. Co. is focused on the development of antibody drug conjugates, including research, development, human clinical trials, regulatory approval and commercialization. Antibody drug conjugates (ADCs) are drug constructs which combine monoclonal antibodies specific to particular types of cells with cytotoxic molecules or warheads which seek to kill cancer cells to which the ADC attaches. Co.'s hematology franchise comprises three clinical-stage product candidates, Lonca, Cami and ADCT-602. Co.'s solid tumor franchise comprises two clinical-stage product candidates, Cami and ADCT-601, and two preclinical product candidates, ADCT-901 and ADCT-701.

20 YEAR PERFORMANCE RESULTS